2.48
+0.11(+4.64%)
Currency In USD
| Previous Close | 2.37 |
| Open | 2.34 |
| Day High | 2.49 |
| Day Low | 2.32 |
| 52-Week High | 3.29 |
| 52-Week Low | 1.66 |
| Volume | 392,771 |
| Average Volume | 429,016 |
| Market Cap | 210.13M |
| PE | -9.19 |
| EPS | -0.27 |
| Moving Average 50 Days | 2.25 |
| Moving Average 200 Days | 2.08 |
| Change | 0.11 |
If you invested $1000 in Stereotaxis, Inc. (STXS) 10 years ago, it would be worth $1,425.29 as of February 05, 2025 at a share price of $2.48. Whereas If you bought $1000 worth of Stereotaxis, Inc. (STXS) shares 5 years ago, it would be worth $603.41 as of February 05, 2025 at a share price of $2.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
GlobeNewswire Inc.
Feb 03, 2025 9:05 PM GMT
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth qua
Stereotaxis Announces First GenesisX Robotic System Order
GlobeNewswire Inc.
Jan 30, 2025 1:09 PM GMT
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robo
Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
GlobeNewswire Inc.
Jan 27, 2025 1:00 PM GMT
ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™ abla